Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Effect of simvastatin on plasma interleukin-6 in patients with unstable angina.
PURPOSE The primary aim of the study was to investigate the effect of sinvastatin on plasma interleukin-6 ( IL-6 ) in patients with unstable angina pectoris ( UAP ) . METHODS Eighty-six patients with UAP were r and omized into simvastatin ( 40 mg/d for 4 weeks ) and the placebo group .  Plasma IL-6 was measured by ELISA . RESULTS There was a reduction in the plasma total cholesterol and LDL in the simvastatin group ( P < 0.01 ) . The simvastatin group also had better angina control than the placebo group ( post-treatment angina score , 0.72+/-0.59 vs 1.07+/-0.76 , P < 0.05 ) . Following treatment , the average left ventricular ejection fraction in the simvastatin group was higher than in the placebo group ( 0.54+/-0.06 vs 0.51+/-0.05 , P < 0.05 ) , whereas the plasma BNP levels were lower ( 16.8+/-6.6 vs 26.4+/-1.4 , P < 0.01 ) . Before treatment , there was no difference in the plasma levels of IL-6 between the simvastatin and the placebo groups ( P > 0.05 ) . Following treatment , the IL-6 levels in the simvastatin group were lower than in the placebo group ( 0.7+/-0.4 vs 1.2+/-0.4 pg/ml , P < 0.05 ) . CONCLUSIONS Short-term treatment with simvastatin reduces plasma IL-6 . The anti-inflammatory effect of simvastatin may contribute to its beneficial effects on the ventricular function and angina control
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .